X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (793) 793
Publication (78) 78
Book Chapter (22) 22
Book Review (7) 7
Conference Proceeding (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (474) 474
index medicus (405) 405
male (245) 245
pharmacology & pharmacy (239) 239
female (233) 233
exposure-response (225) 225
adult (189) 189
middle aged (185) 185
pharmacokinetics (153) 153
analysis (148) 148
public, environmental & occupational health (144) 144
exposure (138) 138
aged (128) 128
dose-response relationship, drug (123) 123
environmental sciences (117) 117
exposure-response relationship (107) 107
exposure-response relationships (94) 94
risk assessment (88) 88
toxicology (80) 80
mortality (77) 77
pharmacology (77) 77
risk factors (77) 77
cancer (75) 75
animals (74) 74
air pollution (69) 69
care and treatment (69) 69
adolescent (67) 67
epidemiology (67) 67
research (66) 66
occupational exposure - adverse effects (65) 65
oncology (65) 65
safety (65) 65
pharmacology/toxicology (64) 64
young adult (63) 63
health aspects (62) 62
models, biological (59) 59
exposure–response (58) 58
treatment outcome (57) 57
occupational exposure (53) 53
pharmacodynamics (53) 53
population pharmacokinetics (53) 53
studies (53) 53
exposure-response analyses (51) 51
regression analysis (50) 50
medicine & public health (49) 49
workers (48) 48
exposure-response analysis (47) 47
risk (47) 47
time factors (46) 46
patients (45) 45
aged, 80 and over (44) 44
exposure response (43) 43
efficacy (42) 42
health (42) 42
microbiology (42) 42
public health (40) 40
double-blind method (38) 38
infectious diseases (38) 38
lung cancer (38) 38
cohort studies (36) 36
immunology (36) 36
medical research (36) 36
particulate matter (36) 36
clinical trials (35) 35
computer simulation (35) 35
article (34) 34
exposure‐response (34) 34
models (34) 34
prevalence (33) 33
dust (32) 32
occupational diseases - epidemiology (31) 31
dose-response effects (30) 30
medicine, experimental (30) 30
occupational exposure - analysis (29) 29
population (29) 29
biomedicine (28) 28
child (28) 28
environmental exposure (28) 28
logistic models (28) 28
asthma (27) 27
model (27) 27
therapeutic drug monitoring (27) 27
annoyance (26) 26
china (26) 26
drug development (26) 26
environmental exposure - adverse effects (26) 26
environmental health (26) 26
minocycline - analogs & derivatives (26) 26
pharmacy (26) 26
retrospective studies (26) 26
statistical analysis (26) 26
air-pollution (25) 25
area under curve (25) 25
cancer research (25) 25
dose response relationship (25) 25
health risk assessment (25) 25
occupational diseases - etiology (25) 25
review (25) 25
transportation noise (25) 25
aircraft noise (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 08/2011, Volume 51, Issue 8, pp. 1152 - 1162
To increase our understanding of important subject characteristics and design variables affecting the performance of oral moxifloxacin in thorough QT studies,... 
Population pharmacokinetics | QT prolongation | exposure—response modeling | thorough QT studies | ICH E14 | moxifloxacin | exposure-response modeling | WOMEN | INTERVAL PROLONGATION | TRAFFICKING | PHARMACOLOGY & PHARMACY | QT/QTC | QUINIDINE | Fluoroquinolones | Aza Compounds - pharmacokinetics | Quinolines - blood | Drugs, Investigational - adverse effects | Anti-Infective Agents - blood | United States | Humans | Middle Aged | Drugs, Investigational - pharmacokinetics | Aza Compounds - adverse effects | Male | Metabolic Clearance Rate | Quinolines - administration & dosage | Drugs, Investigational - analysis | Intestinal Absorption | Delayed-Action Preparations - administration & dosage | Quinolines - pharmacokinetics | Young Adult | Delayed-Action Preparations - pharmacokinetics | Adult | Aza Compounds - blood | Female | United States Food and Drug Administration | Aza Compounds - administration & dosage | Anti-Infective Agents - adverse effects | Administration, Oral | Electrocardiography - drug effects | Clinical Trials as Topic | Animals | Anti-Infective Agents - administration & dosage | Delayed-Action Preparations - adverse effects | Models, Biological | Anti-Infective Agents - pharmacokinetics | Adolescent | Drugs, Investigational - administration & dosage | Aged | Quinolines - adverse effects | Physiological aspects | Moxifloxacin | Research | Demographic aspects | Pharmacokinetics
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2014, Volume 73, Issue 4, pp. 737 - 747
The aim of this study was to characterize trastuzumab population pharmacokinetics (PKs) in patients with human epidermal growth factor receptor 2-positive... 
Population pharmacokinetics | Gastroesophageal junction cancer | Medicine & Public Health | Exposure–response | Oncology | Cancer Research | Pharmacology/Toxicology | Gastric cancer | Trastuzumab | Exposure-response | SURVIVAL | EGF | RECEPTOR | HER-2 | AMPLIFICATION | GENE | ONCOLOGY | PHARMACOLOGY & PHARMACY | rastuzumab | Receptor, ErbB-2 - genetics | Capecitabine | Esophageal Neoplasms - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Esophageal Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Esophagogastric Junction - metabolism | Esophagogastric Junction - pathology | Stomach Neoplasms - drug therapy | Stomach Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Antineoplastic agents | Cancer
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2017, Volume 57, Issue 5, pp. 573 - 583
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 03/2019, Volume 59, Issue 3, pp. 364 - 373
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2019, Volume 59, Issue 5, pp. 748 - 762
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 07/2018, Volume 58, Issue 7, pp. 927 - 938
Eslicarbazepine acetate (ESL) is a once‐daily oral antiepileptic drug (AED) indicated for partial‐onset seizures (POS). ESL pharmacokinetics (PK) and... 
pharmacokinetics | exposure‐response | eslicarbazepine | safety | monotherapy | exposure-response | HYPONATREMIA | PHARMACOLOGY & PHARMACY | EPILEPSY | ANTIEPILEPTIC DRUGS | Seizing | Headache | Diaries | Hyponatremia | Body weight | Nausea | Exposure | Pharmacology | Antiepileptic agents | Sodium | Pharmacokinetics | Acetic acid | Seizures
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2017, Volume 80, Issue 6, pp. 1079 - 1090
In the phase III EMILIA study, trastuzumab emtansine (T-DM1) significantly improved progression-free survival (PFS) and overall survival (OS) versus... 
Human epidermal growth factor receptor 2 (HER2) | Medicine & Public Health | Exposure–response relationship | Trastuzumab emtansine (T-DM1) | Oncology | Cancer Research | Metastatic breast cancer | Pharmacology/Toxicology | Pharmacokinetics | Antibody–drug conjugate (ADC) | ANTIBODY-DRUG CONJUGATE | ONCOLOGY | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | T-DM1 | Antibody-drug conjugate (ADC) | Exposure-response relationship | Bridged-Ring Compounds - therapeutic use | Trastuzumab - therapeutic use | Maytansine - analogs & derivatives | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Taxoids - therapeutic use | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Female | Viral antibodies | Antimitotic agents | Complications and side effects | Care and treatment | Biological products | Epidermal growth factor | Analysis | Antibodies | Breast cancer | Metastasis | Antineoplastic agents | Risk factors | Thrombocytopenia | Effectiveness | Exposure | Taxane | Risk analysis | Patients | Survival | ErbB-2 protein | Quality | Mathematical models | Numerical prediction | Trends | Safety | Risk management | Hepatotoxicity | Trastuzumab | Cancer | Index Medicus
Journal Article
Rheumatology, ISSN 1462-0324, 02/2019, Volume 58, Issue 2, pp. 352 - 360
Abstract Objectives ABT-122 is a dual-variable-domain immunoglobulin that neutralizes both TNF-α and IL-17A. The objective of this work was to characterize... 
PASI | TNF-alpha | SAFETY | MONOCLONAL-ANTIBODY | RHEUMATOLOGY | rheumatoid arthritis | exposure-response | FACTOR-ALPHA | ACR | TUMOR-NECROSIS-FACTOR | RECOMMENDATIONS | IL-17 | DISEASE | pharmacokinetics | psoriatic arthritis | ABT-122 | Clinical trials | Monoclonal antibodies | Markov chains | Tumor necrosis factor-α | Interleukin 17
Journal Article
Journal of Hypertension, ISSN 0263-6352, 06/2012, Volume 30, Issue 6, pp. 1075 - 1086
OBJECTIVE:Reviews have suggested that road noise exposure is associated with high blood pressure (hypertension). No reliable exposure–response relationship is... 
exposure-response relationship | high blood pressure | review | meta-analysis | road traffic noise | hypertension | heterogeneity | SLEEP | TRANSPORTATION NOISE | AIR | AIRCRAFT NOISE | BLOOD-PRESSURE | ANNOYANCE | PERIPHERAL VASCULAR DISEASE | HEALTH | CARDIOVASCULAR RISK | ENVIRONMENTAL NOISE | EXPOSURE | Motor Vehicles | Noise | Humans | Hypertension - etiology
Journal Article